|
|
||||||||||||||
|
|
|||||||||||||||
Therapeutics |
Clinical impact ratings GP/FP/Primary care






IM/Ambulatory care 





Nephrology 





Endocrine 





Key Words: angiotensin converting enzyme inhibitors antihypertensive agents diabetic nephropathies kidney failure (chronic) renin-angiotensin system
| The first 150 words of the full text of this article appear below. |
METHODS
Data sources:
Medline, EMBASE/Excerpta Medica, and the Cochrane Library (1960 to January 2005); and references of relevant studies and reviews.
Study selection and assessment:
randomised controlled trials (RCTs) with
1 year follow up that examined the effect of drug treatment with a BP lowering action on progression of renal disease. 127 RCTs (150 comparisons) with mean follow up of 4.2 years met the selection criteria.
Outcomes:
end stage renal disease (ESRD) (need for kidney transplantation or dialysis) and doubling of serum creatinine.
MAIN RESULTS
Changes in BP were similar across the 5 outcomes; all but 1 showed no difference in the degree of change in systolic and diastolic BP between patients receiving ACE inhibitors or ARBs and those receiving other antihypertensive drugs; ACE inhibitor or ARB treatment led to a reduction in systolic BP of 1.49 mm Hg (95% CI 0.05 to 2.92) in studies with change in creatinine concentration as an
Catherine Clase, MB, BChir1, Amit X Garg, MD, PhD2
1 McMaster University, Hamilton, Ontario, Canada
2 University of Western Ontario, London, Ontario, Canada
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |